Abstract: Low-density lipoprotein-cholesterol (LDL-C) is a well established coronary heart disease (CHD) risk factor. However, the ability of this metabolic risk factor alone to identify individuals at risk for future CHD events is limited. The raised triglycerides-low high-density lipoprotein-cholesterol (HDL-C) dyslipidemia was shown to be an important cardiovascular risk factor independently of LDL-C levels. Fibric acid derivatives (fi brates) have been used in clinical practice for more than 2 decades as a class of agents known to decrease triglyceride levels while substantially increasing HDL-C levels. Through peroxisome proliferator-activated α-receptors, fi brates have a signifi cant impact on the synthesis of several apolipoproteins and enzymes of lipoprotein metabolism as well as on the expression of several genes involved in fi brinolysis and infl ammation. Data from recent primary and secondary prevention clinical trials demonstrate the effi cacy of fi brate therapy in patients with the raised triglycerides-low HDL-C dyslipidemia. This review summarizes current data regarding mechanism of action and the metbolic effects of fi brates, as well as results from major clinical trials on the effi cacy of this mode of lipid lowering therapy. In addition, recent data from subgroup analyses of the Bezafi brate Infarction Prevention trial, demonstrating several important metabolic and long-term cardiovascular effects of bezafi brate therapy, are detailed.
Introduction
Considerable progress in the understanding of coronary heart disease (CHD) risk factors has been made in the past decades, leading to the development of strategies to reduce CHD event rate. The ability of HMG-CoA reductase inhibitors (statins) to reduce the occurrence of CHD in individuals with hypercholesterolaemia has been reported in large primary and secondary prevention trials. Intervention trials using statins to lower low-density lipoprotein cholesterol (LDL-C) have consistently shown substantial reductions in major cardiovascular events in the treated groups (Shepard et al 1995; Sacks et al 1996; Downs et al 1998; Sever et al 2003; Baigent et al 2005) , that was shown to be a function of the extent of LDL-C lowering (Baigent et al 2005) . However, risk reduction with statin therapy is limited to about 30%, and the ability to adequately identify individuals at high risk for the development of CHD by total or LDL-C levels is limited by the fact that almost 50% of CHD patients have serum cholesterol levels in the normal range (Genest et al 1992) . Thus, additional factors appear to modulate the risk of CHD independently LDL-C level.
Early data had shown that low high-density lipoprotein cholesterol (HDL-C) levels are inversely related to CHD incidence in both men and women (Yaari et al 1981; Gordon et al 1997) . It has also been demonstrated that the risk associated with HDL-C is independent of LDL-C levels (Castelli et al 1987) . Furthermore, a recent post hoc analysis from the Treating to New Targets (TNT) study (Barter et al 2007) , has shown that HDL-C levels are predictive of major cardiovascular events even in patients who maintain LDL-C levels below 70 mg/dL while on statin therapy. In the majority of patients with low HDL-C who develop CHD, this lipoprotein alteration is most often accompanied by elevated triglyceride levels (Manninem et al 1992; Jeppesen et al 1997; Gotto et al 1998) . This raised triglycerides-low HDL-cholesterol dyslipidemic state is a common feature of the altered risk profi le of patients with type 2 diabetes, and is largely the consequence of an insulin-resistant state found in viscerally obese patients with the metabolic syndrome (Howard et al 1987; Laakso et al 1990; Bieman et al 1992) . Thus, even in the absence of hyperglycemia or of type 2 diabetes, overweight/obese patients with the features of the metabolic syndrome and the raised triglycerides-low HDL-cholesterol dyslipidemic state have a substantially increased risk of CHD, despite LDL-C levels that are presumably within the 'normal' range (Lammarch et al 1998) . Such dyslipidemia is also characterized by increased levels of atherogenic lipoproteins including, elevated apo B, and small, dense LDL and HDL particles (Tchernof et al 1996) .
It had been known for decades that treatment with fi brates results in substantial decreases in triglyceride levels associated with a moderate increase in HDL-C levels and usually a small reduction in LDL-C levels. This class of drugs has been particularly useful in patients with primary hypertriglyceridemia, mixed hyperlipidemia, and in patients with type 2 diabetes and the raised triglycerides-low HDL-C dyslipidemia (Fruchart et al 1998) . In recent years, signifi cant progress has been made in understanding the mode of action of fi brates. These data have shown that fi brates activate specifi c transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPAR). Activation of these receptors alters the transcription rate of target genes which play a key role in the development of atherosclerosis. Recent data from the Veterans Affairs High- Goldenberg et al 2006; Goldenberg et al 2007) . In this review, the pharmacology of the fi brates is discussed, together with data from recent clinical trials that indicate the potential of the fi brates in general, and bezafibrate specifi cally, in managing dyslipidemia, with a focus on the use of these drugs in the atherogenic dyslipidemia commonly observed in obese, insulin-resistant and diabetic individuals.
Mechanism of action
Fibrates act as synthetic ligands for PPARα, which are mainly located in the liver, skeletal muscle, heart muscle, and cells in the arterial wall that play a key role in the development of atherosclerosis (Vamecq et al 1999; Tennenbaum et al 2003; Berger et al 2005) . PPAR bind as heterodimers with another nuclear receptor, the retinoid X receptor, to specifi c response elements termed peroxisome proliferator response elements and alter the transcription rate of target genes. A summary of PPARα-mediated gene regulation by fi brates is provided in Table 1 .
Effect on plasma lipids and lipoproteins
Fibrates reduce plasma levels of triglycerides by 30%-50% and typically increase levels of HDL-C by 5%-15%, depending on lipid phenotype and baseline concentration. Fibrates may also reduce LDL-C by up to 15%-20% although the effect is variable, depending on the underlying lipid abnormality and baseline lipid phenotype (Chapman et al (Haubenwallner et al 1995; Staels et al 1995a; Stael et al 1998; Chapman et al 2006) . Fibrate therapy also promotes the β-oxidation of fatty acids, thus reducing the availability of free fatty acids for triglyceride synthesis (Schoonjans et al 1996) . In addition, de novo fatty acid synthesis is inhibited through reductions in acetyl-CoA carboxylase and fatty acid synthase activity; thereby reducing the availability of fatty acids for triglyceride synthesis (Schoonjans et al 1996a; Schoonjans et al 1996b) . PPARα activation also increases ApoAI and ApoAII synthesis (the major proteins in HDL) (Schoonjans et al 1996a; Schoonjans et al 1996b) . Cholesteryl ester transfer protein (CETP) activity was found to be reduced with fi brate therapy (Kiyanagi et al 2006) ; and the reduction in CETP-mediated transfer of lipid from HDL-C to very (V) LDL may also contribute to the observed increase in HDL-C levels.
Effects on LDL and HDL particle subclasses Evidence suggests that LDL particle subclasses may differ in atherogenicity, with small, dense LDL associated with greater CHD risk than large, buoyant LDL. The larger particles have a high binding affi nity for cellular LDL receptors, and are less susceptible to oxidation. Individuals with the metabolic syndrome and the raised triglycerides-low HDL-C dyslipidemia characteristically have LDL particles that are smaller and contain less cholesterol than average (Berneis et al 2002) . As a result, the number of atherogenic LDL particles is frequently elevated in this population, even though LDL-C levels are not. Cardiovascular risk was found to be better explained by concentrations of LDL particles or plasma levels of apolipoprotein B (ApoB), than by LDL-C (Berneis et al 2002; Blake et al 2002; . Fibrate therapy was shown to alter LDL subclass distribution among normolipemic subjects with predominantly dense LDL-C (Superko et al 2005) , resulting in a reduction in small dense LDL and an opposite effect on HDL subclass distribution (Guérin et al 1996) . In a substudy of VA-HIT (Otvos et al 2006) , treatment with gemfi brozil was associated with an increase LDL size and a reduction in the number of LDL particles by 5%, while raising the number of HDL particles by approximately 10% and of small HDL subclass particles by 21%. Furthermore, concentrations of these LDL and HDL particles achieved with gemfi brozil were shown to be signifi cant, independent, predictors of major cardiac events and helped explain the demonstrated benefi t of fi brate therapy in this population. Other studies have shown that treatment with fenofi brate, ciprofi brate, and bezafi brate also exert a benefi cial effect on LDL subclass distribution. Notably, among the different agents, fenofi brate has been found to be particularly effective in modulating LDL size and subclasses .
Non-lipid effects
Fibrates were shown to exert pleiotropic effects in the artery wall. PPARα is involved in the control of the antiinfl ammatory response, via inhibition of the transcription factor NFκB (Chapman 2003) , and to attenuate the production of pro-infl ammatory stimuli such as interleukin 6 and various prostaglandins, as well as the acute phase proteins, including fi brinogen and C-reactive protein (Devchand et al 1996; Staels et al 1998) .
Fibrates have favorable effects on coagulation and fi brinolysis. Bezafi brate was shown to reduce levels of fi brinogen by up to 20% (Schonfeld et al 1994) , and ciprofi brate and fenofi brate have been shown to increase fi brinolysis and attenuate platelet hyperaggregability in hypercholesterolemic subjects (Simpson et al 1998) .
Adverse effects and precautions
Common adverse reactions of fibrate therapy include gastrointestinal (epigastric distress, flatulence, nausea, diarrhea, constipation) and dermatologic (pruritus, urticaria, or erythema) symptoms, whereas reactions related to the musculoskeletal (muscular weakness, pain, and muscle cramps) and neurological (headache, dizziness) systems are less common. Several specifi c precautions are listed below.
Hematologic changes
Mild hemoglobin, leukocyte and platelet decreases have occurred occasionally following initiation of bezafi brate therapy. However, these levels stabilize during long-term administration. Periodic blood counts are recommended during the fi rst 12 months of administration.
Liver function
Abnormal liver function tests have been observed occasionally during fi brate administration, including elevated transaminases, and decreased or, rarely, increased alkaline phosphatase. However, these abnormalities are reversible upon discontinuation of the drug. Therefore, periodic liver function tests (AST, ALT, and GGT [if originally elevated]) in addition to other baseline tests are recommended after 3-6 months and at least yearly thereafter. Fibrate therapy should be terminated if drug-related abnormalities persist.
Cholelithiasis
Fibrates may increase cholesterol excretion into the bile, and may lead to cholelithiasis. If such is suspected, gallbladder studies are indicated. Fibrate therapy should be discontinued if gallstones are found.
Hepatobiliary disease
In patients with a past history of jaundice or hepatic disorder, fi brates should be used with caution.
Skeletal muscle
Treatment with drugs of the fi brate class has been associated on rare occasions with myositis or rhabdomyolysis, usually in patients with impaired renal function. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness/weakness, or marked elevations in creatinine phosphokinase (CPK) levels. Patients should be advised to report unexplained muscle pain, tenderness or weakness promptly, particularly if accompanied by malaise or fever. Levels of CPK should be assessed in patients reporting these symptoms, and fi brate therapy should be discontinued if markedly elevated CPK levels (10 times the upper limit of normal) occur or myopathy is diagnosed.
Children
Limited experience is available in children. Therefore, in the absence of adequate information concerning the long-term safety, fi brates should be used with caution in treating this population.
Fibrate therapy Pregnancy and lactation
Strict birth control procedures must be exercised by women of childbearing potential. If pregnancy occurs despite birth control procedures, fi brate therapy should be discontinued. Women planning a pregnancy should discontinue fi brate therapy several months prior to conception. In the absence of data concerning the presence of fi brates in human breast milk, the drugs should not be used by nursing mothers.
Clinical trials
Fibrates have been in clinical use for over 30 years. Clofi brate was introduced in the 1970s and was followed by gemfi brozil, bezafi brate, fenofi brate and ciprofi brate. Although there have been fewer intervention studies with fi brates than with statins, the majority of available evidence indicate long-term beneficial effects in high-risk patients with the raised triglycerideslow HDL-C dyslipidemia of the metabolic syndrome, both in primary and secondary intervention settings. A summary of data from major randomized trials of fi brate therapy is provided in Table 2 .
Primary prevention
Clofi brate and gemfi brozil have been investigated in a primary prevention setting in the general population (Table 2 ). In the WHO Clofi brate Study (Committee of Principal Investigators 1978), 10,627 men without CHD treated with clofi brate for 5 years showed a 25% reduction in myocardial infarction (MI) and a 20% reduction in fi rst major coronary event. These benefi cial results were, however, overshadowed by the reported increase in mortality from non-cardiovascular disease, particularly cancer (Committee of Principal Investigators 1978), although subsequent follow-up showed a smaller difference in cancer incidence between the clofi brate and control groups (Committee of Principal Investigators 1978).
The Helsinki Heart Study (Frick et al 1987) was a placebo-controlled study, including more than 4,000 men at moderate risk of CHD with a range of lipid patterns, but generally with an elevated LDL-C level. The study showed that treatment with gemfi brozil (1,200 mg/day), resulted in an 11% decrease in LDL-C, a 35% decrease in triglycerides and an 11% increase in HDL-C, compared with placebo. These lipid changes were associated with a 34% reduction in major coronary events at fi ve years (p Ͻ 0.02), as well as a 37% reduction in non-fatal MI (p Ͻ 0.05). No signifi cant difference in overall mortality was observed between the two groups.
Secondary prevention
The value of fi brate therapy in the secondary prevention setting is supported by numerous studies (Table 2) . Two small trials of clofi brate therapy, Newcastle (Trial of clofi brate in the treatment of ischemic heart disease 1971) and Edinburgh (Trial of clofi brate in the treatment of ischemic heart disease), failed to fi nd a signifi cant reduction in CHD deaths, but did fi nd that clofi brate prevented nonfatal-MI to a variable extent. The Coronary Drug Project (CDP) (Clofi brate and niacin in coronary heart disease 1975) was a larger secondary prevention trial that showed a non-signifi cant reduction in CHD events with clofi brate therapy. However, a late lipid-lowering therapy effect was observed in an extended follow-up of the trial (Canner et al 1986) , nine years after termination of the trial. The authors attributed this to the transformation of an early favorable effect of niacin in decreasing nonfatal reinfarction, into a mortality benefi t over subsequent years. In the Stockholm Ischaemic Heart Disease Secondary Prevention Study (Carlson et al 1988) , combination treatment with clofi brate (2 g/day) and nicotinic acid (3 g/day) was investigated in 555 post-MI patients (279 received active treatment). Compared with a control group, active treatment reduced triglycerides by 19% and signifi cantly reduced total and CHD mortality by 26% (p Ͻ 0.05) and 36% (p Ͻ 0.01), respectively. Notably, CHD risk reduction was only evident in patients with triglyceride levels higher than the median value at baseline; subjects in whom triglyceride levels were reduced by more than 30% (over 40% of treated patients) experienced a 60% reduction in CHD mortality (p Ͻ 0.01). Subsequently, VA-HIT (Rubins et al 1999) , involving 2,531 men with established CHD, acceptable LDL-C levels, low HDL-C, and elevated triglycerides ( Table 2 ), showed that treatment with gemfibrozil produced a significant 22% reduction in the risk of the primary end point of CHD death or non-fatal MI, as well as CHD mortality. It is noteworthy that 25% of patients enrolled in VA-HIT had diagnosed diabetes and over 50% of patients had features of the metabolic syndrome. The BIP study (The BIP Study Group 2000; also described separately in the following section) comprised 3090 patients allocated to bezafi brate (400 mg/day) or placebo. A signifi cant reduction in plasma triglyceride levels and an increase in HDL-C were observed in this study although there was no signifi cant difference in the fi ve-year coronary event rate compared with placebo (9.4% reduction, p = 0.26). However, bezafi brate was shown to be particularly benefi cial among patients with elevated triglycerides (Ͼ200 mg/dL) at baseline, in whom a 40% reduction in coronary risk at fi ve years was observed. Ericsson et al 1996) , was a relatively small trial designed to evaluate the effects of treatment with bezafi brate on angiographic disease in 92 young male MI survivors. The study showed a signifi cant reduction in the progression of coronary atherosclerosis, as assessed by the change in minimum lumen diameter, in patients treated with bezafi brate compared with placebo. In the Lopid Coronary Angiography Trial (Frick et al 1997) , 395 men with low HDL-C and LDL-C levels who had previously undergone CABG, were treated with gemfi brozil (1200 mg/day). The study medication was associated with signifi cantly decreased progression of coronary artery disease in native coronary segments compared with placebo.
Type 2 diabetes
The pharmacological profi le of the fi brates, described above, suggests that these agents may prove useful in correcting the atherogenic dyslipidemia typically associated with type 2 diabetes and the metabolic syndrome.
Subgroup analyses of data from the Helsinki Heart Study (Koskinen et al 1992) and VA-HIT (Rubins et al 2002) showed that among patients with type 2 diabetes, treatment with gemfi brozil was associated with a signifi cant reduction in the risk of coronary events that ranged from 68% (Koskinen et al 1992) in the primary intervention setting to 32% (Rubins et al 2002) in the secondary prevention setting. In the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Prevention (SENDCAP) study (Elkeles et al 1998) , 164 type 2 diabetes patients without a history of CHD, treated with bezafi brate (400 mg/day) for three years, had a lower CHD event rate compared with placebo (7% vs. 23%, p = 0.01). There was, however, no difference between the groups in progression of carotid and femoral artery atherosclerosis, as assessed by changes in intima-media thickness.
Fibrate therapy
More recently, the Diabetes Atherosclerosis Intervention Study ([DAIS] Vakkilainen et al 2003) , involving 418 patients with type 2 diabetes has provided clear evidence of the value of fi brate therapy in diabetic patients. Treatment with micronised fenofi brate, at a dose of 200 mg/day for at least 3 years, was associated with a 40% reduction in angiographic progression of coronary artery disease, as well as a 23% reduction in the cardiovascular event rate, compared with placebo. These benefi cial effects were associated with reduction in the levels of triglycerides (by 29%) and LDL-C (by 5%), and an increase in HDL-C (by 7%) and LDL particle size (Vakkilainen et al 2003) .
The Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) study (The FIELD study investigators 2005) evaluated the role of fi brate therapy in preventing cardiovascular events in patients with type 2 diabetes, considered at increased risk for CHD. After a mean follow-up of 5 years, therapy with fenofi brate was associated wuth a non-signifi cant 11% reduction in the primary end point of nonfatal MI or CHD death. However, total cardiovascular events, corresponding to the secondary end point, were signifi cantly reduced with fenofi brate by 11% (p = 0.035), mainly due to signifi cant reductions in non-fatal MI (by 24%, p = 0.01) and coronary revascularization (by 21%, p = 0.003). Treatment effects were larger in patients without cardiovascular disease than in those with a history of cardiovascular disease. Notably, end points that concerned microangiographic manifestations of diabetes were significantly improved by fenofi brate treatment; these included a reduction in the need for laser treatment for retinopathy and reduction in the progression of albuminuria.
Bezafi brate therapy: recent data from the BIP trial
Bezafi brate was the fi rst clinically tested pan -(alpha, beta/delta, gamma) PPAR activator (Peters et al 2000; The BIP Study Group 2000; Cobrero et al 2001; Poirier 2001; Vazquez 2001) , and is a sole pan PPAR activator with more than a quarter of a century of a therapeutic experience with a good safety profi le. The BIP study was designed to determine whether bezafi brate would reduce CHD mortality and nonfatal MI in CHD patients with low HDL-C and LDL-C in a moderate range (The BIP Study Group 2000) . The study demonstrated fewer cardiac events with bezafi brate (13.6%) as compared with placebo (15.0%) during a 6.2-year mean follow-up period. However, event rate was not signifi cantly reduced (p = 0.26) despite reductions of 5% in LDL-C, 16% in triglyceride, and 10% in fi brinogen levels, together with an increase of 14% in HDL-C levels compared with placebo. A post hoc analysis in patients with high baseline triglycerides (200 mg/dL) revealed that the reduction in the cumulative probability of the primary end point by bezafi brate was 39.5% (p = 0.02) in that subgroup.
There are several explanations for the differences in outcome between VA-HIT and BIP in addition to the difference in the type of fi brate drug. First, LDL-C levels in BIP were in a moderately high range at baseline (averaging 149 mg/dL), necessitating a relatively large prescription rate of "off-trial" lipid lowering therapies, mainly in the placebo group (15% of placebo-allocated patients received active lipid therapy by the end of the study), thereby attenuating the margin of difference in outcome between the placebo and active treatment groups. Second, differences in patient characteristics might have affected outcome in the 2 trials: BIP excluded individuals with diabetes and higher levels of blood glucose as well as recruited fewer individuals with components of the metabolic syndrome, in whom the effi cacy of fi brate therapy is enhanced, resulting in a lower event rate during follow-up. Despite these differences in trial design, recent subgroup analyses from BIP revealed several important fi ndings regarding the long-term cardiovascular effects of bezafi brate that are described below.
Relationship between on-treatment increments in serum HDL-cholesterol levels and cardiac mortality
In a subanalysis of BIP we evaluated the relationship between changes in serum levels of HDL-C under bezafibrate therapy and cardiac mortality in enrolled subjects (Goldenberg et al 2006) . Long-term follow-up revealed that cardiac mortality was signifi cantly reduced with increasing increments of on-treatment HDL-C change (9.5%, 6.6%, and 6.3% of patients died of cardiac causes in tertiles 1, 2, and 3 of HDL-C increase, respectively [p for trend = 0.02]); Figure 2 ). The magnitude of on-treatment HDL-C increment in the trial was shown to be independently associated with reduced risk of cardiac death: patients who did not respond to bezafi brate therapy by increasing serum HDL-C levels (tertile 1 HDL-C change) did not experience a survival benefi t with bezafi brate therapy (hazard ratio: 1.05 [95% CI 0.74-1.47]), whereas responders (tertile 3 HDL-C increase) experienced a signifi cant 35% reduction in the risk of cardiac death with bezafi brate ). Furthermore, the risk of cardiac mortality was reduced by 27% for every 5 mg/dL increase in on-treatment HDL-C change (p Ͻ 0.001). Thus, these fi ndings demonstrate an Goldenberg et al Figure 2 All-cause and cardiac mortality rates in tertiles of HDL-C change in the bezafi brate group compared to the placebo group. *p for trend Ͻ 0.05 Reprinted with permission from Goldenberg et al (2006) . independent association between a rise in HDL-C with bezafi brate therapy and a reduction in cardiac mortality, and suggest that monitoring short-term response to bezafi brate therapy through HDL-C change may indicate the potential long-term benefi t of the drug.
Long-term cardioprotective effects of bezafi brate therapy
We have recently completed an evaluation of the effect of bezafi brate therapy over an extended follow-up period of BIP (Goldenberg et al 2007) . After discontinuation of study medication, patients were observed for coronary events for an additional period, bringing the total follow-up time in the current analysis to a mean of 8.2 years (median: 7.9 years; interquartile range: 7.2-8.7 years). Our data demonstrate that during long-term follow-up bezafi brate therapy was associated with a signifi cant 17% reduction (p = 0.03) in the combined end point of cardiac death or nonfatal MI (Figure 3) . Using interaction-term analysis, we have also shown that the benefi t of bezafi brate therapy was pronounced (18% risk reduction; p = 0.03) without-or before-treatment with off-trial lipid lowering therapies was initiated during follow-up, and attenuated (HR = 1.05; p = 0.85) after therapy with off-trial lipid lowering therapies was initiated during the observation period. These new data suggest that bezafi brate therapy is associated with signifi cant long-term cardiovascular protection that may extend beyond the period of active drug therapy.
Effect of bezafi brate therapy in patients with the metabolic syndrome
A post hoc analysis of BIP evaluated the effect of bezafibrate on the incidence of MI during long-term follow-up in enrolled patients with metabolic syndrome (Tenenbaum et al 2005) . Patients who displayed at least 3 of the following 5 risk factors were considered to have metabolic syndrome: (1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); (2) a triglyceride level of 150 mg/dL (1.70 mmol/L); (3) HDL-C level less than 40 mg/dL in men or less than 50 mg/dL in women; (4) a systolic blood pressure of 130 mm Hg or diastolic blood pressure of 85 mm Hg; and (5) a body mass index of 28.0 kg/m 2 . During the course of the extended follow-up period bezafi brate was associated with a signifi cant reduction in the risk of MI, and of the combined primary endpoint of BIP, which consisted of nonfatal MI or sudden cardiac death, among patients with at least 3 risk (Figure 4) . Furthermore, the benefi t of bezafi brate therapy was shown to be enhanced in patients with augmented features (at least 4 risk factors) of the metabolic syndrome (56% reduction of cardiac mortality during 8-year follow-up), whereas the benefi t of bezafi brate was attenuated in patients without features of the metabolic syndrome.
Bezafi brate therapy for the prevention of type 2 diabetes mellitus in patients with coronary artery disease
In a recent study from BIP we evaluated whether pharmacological intervention with bezafi brate that infl uences primary lipid metabolism can also delay development of type 2 diabetes (Tenenbaum et al 2004) . The study comprised 303 non-diabetic study patients with a fasting blood glucose level of 110 to 125 mg/dL, who were allocated to either 400 mg bezafi brate (n = 156) or placebo (n = 147 patients) once a day. During follow-up, development of new-onset diabetes occurred at a signifi cantly lower rate among bezafi brate allocated patients as compared with placebo ( Figure 5 ). The mean time until onset of new diabetes was signifi cantly delayed among the former subgroup as compared with the latter: 4.6 ± 2.3 versus 3.8 ± 2.6 years, respectively, (p = 0.004), and bezafi brate therapy was shown to be associated with a signifi cant 30% reduction in the risk of new diabetes development. These fi ndings suggest that treatment with fi brates may reduce the incidence and delay the onset of type 2 diabetes in patients with impaired fasting glucose, and need to be validated in future prospective studies.
Conclusions and future perspectives
With the epidemic proportions of obesity, especially highrisk abdominal obesity, type 2 diabetes and the metabolic syndrome, it is important to consider lipid lowering therapies that affect the dyslipidemic profi le found in these patients, independently of LDL-C. Data from recent major clinical trials have shown that fi brates produce benefi cial effects on atherogenic lipoproteins through activation of PPARα, and confer long-term cardiovascular protection, both in the primary-and secondary-prevention setting. Therefore, this mode of lipid-lowering therapy should be considered part of an optimal management plan in a signifi cant proportion of patients with a high-risk metabolic profi le. Recent data from the BIP trial have demonstrated several important fi ndings regarding the benefi t of this fi bric acid derivative in CHD patients, including (1) long-term cardioprotective effects that extend beyond the period of active drug therapy; (2) enhanced effi cacy in "responders" (patients in whom HDL-C levels increase in response to bezafi brate therapy; (3) enhanced effi cacy in patients with elevated triglycerides and those with clinical and laboratory features suggestive of the metabolic syndrome; and (4) a signifi cant reduction in the incidence of new onset of type 2 diabetes in patients with impaired fasting glucose.
Further studies are needed to compare the benefi t of statin versus fi brate therapy, or the combination of both classes of drugs, in different subpopulations of patients with a high-risk metabolic profi le. 
